Trial Outcomes & Findings for Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003) (NCT NCT01982630)

NCT ID: NCT01982630

Last Updated: 2022-03-08

Results Overview

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. AEs are presented by individual dose received by participants during titration in an assigned study treatment sequence.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

87 participants

Primary outcome timeframe

Up to approximately 42 days

Results posted on

2022-03-08

Participant Flow

This study had 2 parts: Part 1 evaluated MK-8521, placebo, and liraglutide in participants with Type 2 diabetes mellitus (T2DM); Part 2 evaluated MK-8521 at higher doses, liraglutide, and placebo in participants with T2DM and MK-8521 in non-diabetic, obese participants.

Participant flow, baseline characteristic, and outcome measure data are presented by study treatment sequence. Adverse events are presented by the individual doses contained in the study treatment sequence.

Participant milestones

Participant milestones
Measure	Part 1: MK-8521 64/120 μg/Day Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.	Part 1: MK-8521 34/72 μg/Day T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14.	Part 1: Liraglutide 0.6/1.2/1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.	Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64/120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14.
Overall Study STARTED	10	8	13	9	19	14	6	8
Overall Study Treated	9	8	11	9	18	14	6	8
Overall Study COMPLETED	7	8	8	8	16	11	5	8
Overall Study NOT COMPLETED	3	0	5	1	3	3	1	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: MK-8521 64/120 μg/Day Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.	Part 1: Liraglutide 0.6/1.2/1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.	Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.
Overall Study Adverse Event	2	1	0	1	2	1
Overall Study Physician Decision	1	2	1	2	0	0
Overall Study Did Not Receive Drug-Technical Issues	0	2	0	0	0	0
Overall Study Withdrawal by Subject	0	0	0	0	1	0

Baseline Characteristics

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: MK-8521 64/120 μg/Day n=10 Participants Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.	Part 1: MK-8521 34/72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14.	Part 1: Liraglutide 0.6/1.2/1.8 mg/Day n=13 Participants T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.	Part 1: Placebo for MK-8521 n=9 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM n=19 Participants T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.	Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM n=14 Participants T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.	Part 2: Placebo for MK-8521-T2DM n=6 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64/120 µg/Day-Non-Diabetic Overweight/Obese n=8 Participants Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14.	Total n=87 Participants Total of all reporting groups
Age, Continuous	52.1 Years STANDARD_DEVIATION 8.6 • n=93 Participants	55.0 Years STANDARD_DEVIATION 6.4 • n=4 Participants	54.5 Years STANDARD_DEVIATION 8.8 • n=27 Participants	51.3 Years STANDARD_DEVIATION 9.0 • n=483 Participants	54.6 Years STANDARD_DEVIATION 6.0 • n=36 Participants	54.6 Years STANDARD_DEVIATION 7.9 • n=10 Participants	52.8 Years STANDARD_DEVIATION 6.9 • n=115 Participants	37.9 Years STANDARD_DEVIATION 14.1 • n=40 Participants	52.3 Years STANDARD_DEVIATION 9.4 • n=8 Participants
Sex: Female, Male Female	5 Participants n=93 Participants	2 Participants n=4 Participants	5 Participants n=27 Participants	6 Participants n=483 Participants	11 Participants n=36 Participants	9 Participants n=10 Participants	2 Participants n=115 Participants	2 Participants n=40 Participants	42 Participants n=8 Participants
Sex: Female, Male Male	5 Participants n=93 Participants	6 Participants n=4 Participants	8 Participants n=27 Participants	3 Participants n=483 Participants	8 Participants n=36 Participants	5 Participants n=10 Participants	4 Participants n=115 Participants	6 Participants n=40 Participants	45 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	8 Participants n=93 Participants	8 Participants n=4 Participants	12 Participants n=27 Participants	8 Participants n=483 Participants	11 Participants n=36 Participants	8 Participants n=10 Participants	4 Participants n=115 Participants	4 Participants n=40 Participants	63 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2 Participants n=93 Participants	0 Participants n=4 Participants	1 Participants n=27 Participants	0 Participants n=483 Participants	8 Participants n=36 Participants	6 Participants n=10 Participants	2 Participants n=115 Participants	4 Participants n=40 Participants	23 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	1 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	1 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	1 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	6 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	1 Participants n=483 Participants	1 Participants n=36 Participants	4 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=40 Participants	13 Participants n=8 Participants
Race (NIH/OMB) White	4 Participants n=93 Participants	8 Participants n=4 Participants	13 Participants n=27 Participants	8 Participants n=483 Participants	17 Participants n=36 Participants	10 Participants n=10 Participants	5 Participants n=115 Participants	8 Participants n=40 Participants	73 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants

PRIMARY outcome

Timeframe: Up to approximately 42 days

Population: The analysis population included all participants in Part 1 who received at least one dose of study drug.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=9 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=7 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day n=11 Participants T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day n=11 Participants T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day n=8 Participants T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 n=8 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Number of Participants Experiencing Adverse Events (AEs) in Part 1	5 Participants	5 Participants	1 Participants	4 Participants	2 Participants	7 Participants	2 Participants	5 Participants	—	—	—

PRIMARY outcome

Timeframe: Up to approximately 57 days

Population: The analysis population included all participants in Part 2 who received at least one dose of study drug.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=18 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=18 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=18 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day n=15 Participants T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day n=14 Participants T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day n=13 Participants T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 n=13 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM n=6 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese n=8 Participants Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese n=8 Participants Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Number of Participants Experiencing Adverse Events (AEs) in Part 2	8 Participants	14 Participants	6 Participants	13 Participants	8 Participants	8 Participants	8 Participants	12 Participants	3 Participants	2 Participants	4 Participants

PRIMARY outcome

Timeframe: Up to approximately 14 days

Population: The analysis population included all participants in Part 1 who received at least one dose of study drug.

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. Discontinuations are presented by individual dose received by participants during titration in an assigned study treatment sequence.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=9 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=7 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day n=11 Participants T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day n=11 Participants T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day n=8 Participants T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 n=8 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 1	2 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—

PRIMARY outcome

Timeframe: Up to approximately 29 days

Population: The analysis population included all participants in Part 2 who received at least one dose of study drug.

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. Discontinuations are presented by individual dose received by participants during titration in an assigned study treatment sequence.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=18 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=18 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=18 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day n=15 Participants T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day n=14 Participants T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day n=13 Participants T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 n=13 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM n=6 Participants T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese n=8 Participants Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese n=8 Participants Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 2	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 7 dose

Semi-recumbent heart rate was assessed at baseline on Day 1; Day 7 at predose, 2, 4, 6, 8, 12, 13, 14, 15, 16, 22 hours postdose; and prior to dosing on Day 8. Heart rate was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged before conducting the statistical analysis. TWA0-24hr was calculated as the area under the measurement-time curve (AUC) divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 7 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=6 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	7.19 Beats per minute Interval 3.48 to 10.89	1.17 Beats per minute Interval -2.21 to 4.55	7.42 Beats per minute Interval 3.74 to 11.09	5.69 Beats per minute Interval 2.39 to 8.99	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 7 dose

Population: The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the TWA0-24hr analysis of heart rate.

Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 7: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 8. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 7 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	1.99 Beats per minute Interval 0.1 to 3.88	4.10 Beats per minute Interval 1.87 to 6.34	-0.54 Beats per minute Interval -3.8 to 2.73	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 14 dose

Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, 13, 14, 15, 16, 22 hours postdose and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 14 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=6 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	9.67 Beats per minute Interval 5.97 to 13.37	3.90 Beats per minute Interval 0.52 to 7.28	10.32 Beats per minute Interval 6.65 to 14.0	9.81 Beats per minute Interval 6.51 to 13.12	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 14 dose

Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, 16, hours postdose; and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 14 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	5.05 Beats per minute Interval 2.79 to 7.3	5.93 Beats per minute Interval 3.27 to 8.6	-0.20 Beats per minute Interval -4.32 to 3.93	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 19 dose

Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 19: predose, 2, 4, 6, 8, 12, 16, hours post dose; and prior to dosing on Day 20. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 19 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 19 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	5.62 Beats per minute Interval 3.19 to 8.05	6.20 Beats per minute Interval 3.32 to 9.07	-2.14 Beats per minute Interval -6.66 to 2.37	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 24 dose

Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 24: predose, 2, 4, 6, 8, 12, 16, hours postdose; and prior to dosing on Day 25. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 24 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=17 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 24 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	7.30 Beats per minute Interval 4.43 to 10.17	5.95 Beats per minute Interval 2.5 to 9.41	-0.99 Beats per minute Interval -6.28 to 4.29	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 29 dose

Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; and Day 29: predose, 2, 4, 6, 8, 12, 16 and 24 hours postdose. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 29 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 29 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	8.30 Beats per minute Interval 5.31 to 11.29	5.84 Beats per minute Interval 2.26 to 9.43	-1.31 Beats per minute Interval -6.81 to 4.19	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 7 dose

PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 7: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 8. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 7 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Peak Heart Rate (PHR) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	7.94 Beats per minute Interval 5.76 to 10.13	11.91 Beats per minute Interval 9.3 to 14.53	8.65 Beats per minute Interval 4.86 to 12.43	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 14 dose

PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 14 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Peak Heart Rate (PHR) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	11.41 Beats per minute Interval 8.5 to 14.32	13.00 Beats per minute Interval 9.58 to 16.41	8.90 Beats per minute Interval 3.87 to 13.93	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 19 dose

PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 19: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 20. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 19 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Peak Heart Rate (PHR) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	11.26 Beats per minute Interval 8.28 to 14.24	14.75 Beats per minute Interval 11.25 to 18.25	7.30 Beats per minute Interval 2.0 to 12.61	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 24 dose

PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 24: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 25. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 24 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=17 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Peak Heart Rate (PHR) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	14.09 Beats per minute Interval 10.6 to 17.57	14.06 Beats per minute Interval 9.85 to 18.27	9.39 Beats per minute Interval 3.03 to 15.76	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and up to 24 hours post Day 29 dose

PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; and Day 29: predose 2, 4, 6, 8, 12, 16, and 24 hours post dose. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 29 minus baseline where baseline was defined as predose on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Peak Heart Rate (PHR) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	16.01 Beats per minute Interval 12.88 to 19.13	12.66 Beats per minute Interval 8.91 to 16.41	7.13 Beats per minute Interval 1.49 to 12.76	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and Day 8 (24 hours after Day 7)

Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 7 dose (predose Day 8) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 7 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	1.65 Beats per minute Interval -1.0 to 4.29	5.20 Beats per minute Interval 2.07 to 8.33	0.59 Beats per minute Interval -3.99 to 5.18	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and Day 15 (24 hours after Day 14)

Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 14 dose (predose Day 15) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 14 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	4.22 Beats per minute Interval 1.58 to 6.87	5.38 Beats per minute Interval 2.25 to 8.51	-4.42 Beats per minute Interval -9.32 to 0.47	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and Day 20 (24 hours after Day 19)

Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 19 dose (predose Day 20) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=12 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 19 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	6.41 Beats per minute Interval 3.76 to 9.05	10.44 Beats per minute Interval 7.24 to 13.65	-3.82 Beats per minute Interval -8.72 to 1.07	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and Day 25 (24 hours after Day 24)

Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 24 dose (predose Day 25) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 24 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	7.51 Beats per minute Interval 4.77 to 10.25	9.63 Beats per minute Interval 6.35 to 12.91	-5.82 Beats per minute Interval -10.72 to -0.93	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline (predose Day 1) and Day 30 (24 hours after Day 29)

Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 29 dose minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 29 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	9.41 Beats per minute Interval 6.67 to 12.15	7.30 Beats per minute Interval 4.01 to 10.58	-1.02 Beats per minute Interval -5.92 to 3.87	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1, 7, and 14

AUC0-24hr was the area under the concentration-time curve of MK-8521 from time zero to 24 hours after administration. Plasma samples were collected from predose to 24 hours postdose for determination of AUC0-24hr. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. AUC0-24hr is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=9 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 1	6.11 nM•hour Geometric Coefficient of Variation 47.6	2.25 nM•hour Geometric Coefficient of Variation 27.5	—	—	—	—	—	—	—	—	—
Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 7	14.4 nM•hour Geometric Coefficient of Variation 55.9	5.63 nM•hour Geometric Coefficient of Variation 24.6	—	—	—	—	—	—	—	—	—
Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 14	32.8 nM•hour Geometric Coefficient of Variation 42.8	12.6 nM•hour Geometric Coefficient of Variation 26.6	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7

Cmax was the maximum observed concentration of MK-8521 in plasma after administration. Plasma samples were collected from predose to 24 hours postdose for determination of Cmax. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=9 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Maximum Concentration (Cmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 1	0.350 nM Geometric Coefficient of Variation 41.4	0.128 nM Geometric Coefficient of Variation 21.4	—	—	—	—	—	—	—	—	—
Maximum Concentration (Cmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 7	0.710 nM Geometric Coefficient of Variation 57.6	0.275 nM Geometric Coefficient of Variation 31.2	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14

Cmax was the maximum observed concentration of MK-8521 in plasma after administration on Day 14. Plasma samples were collected from predose to 120 hours postdose for determination of Cmax. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=7 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Maximum Concentration (Cmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	1.70 nM Geometric Coefficient of Variation 38.4	0.619 nM Geometric Coefficient of Variation 27.0	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose on Days 2, 7, and 14

Ctrough was the lowest observed concentration of MK-8521 in plasma. Plasma samples were collected predose on Day 2 (sampled after the Day 1 dose and prior to Day 2 dose), 7, and 14 for determination of Ctrough. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Ctrough is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=9 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Trough Concentration (Ctrough) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 1	0.322 nM Geometric Coefficient of Variation 33.2	0.119 nM Geometric Coefficient of Variation 20.6	—	—	—	—	—	—	—	—	—
Trough Concentration (Ctrough) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 14	1.16 nM Geometric Coefficient of Variation 43.3	0.506 nM Geometric Coefficient of Variation 27.5	—	—	—	—	—	—	—	—	—
Trough Concentration (Ctrough) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 7	0.442 nM Geometric Coefficient of Variation 83.6	0.207 nM Geometric Coefficient of Variation 21.8	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7

Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 24 hours postdose for determination of Tmax. Tmax is presented as median with a full range.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=9 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Time to Maximum Concentration (Tmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 1	16 Hours Interval 10.0 to 24.0	16 Hours Interval 10.0 to 24.0	—	—	—	—	—	—	—	—	—
Time to Maximum Concentration (Tmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1 Day 7	7 Hours Interval 6.0 to 10.0	6 Hours Interval 1.0 to 10.0	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14

Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 120 hours postdose for determination of Tmax. Tmax is presented as median with a full range.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=7 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Time to Maximum Concentration (Tmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	8 Hours Interval 1.0 to 8.0	6 Hours Interval 4.0 to 12.0	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose and 1, 2, 6, 10, 16, and 24 hours postdose on Days 1, 7, and 14

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 7	15.1 nM•hour Geometric Coefficient of Variation 35.6	15.0 nM•hour Geometric Coefficient of Variation 35.9	—	—	—	—	—	—	—	—	—
Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 14	30.0 nM•hour Geometric Coefficient of Variation 35.8	34.4 nM•hour Geometric Coefficient of Variation 19.5	—	—	—	—	—	—	—	—	—
Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 1	6.46 nM•hour Geometric Coefficient of Variation 49.5	7.68 nM•hour Geometric Coefficient of Variation 34.8	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose and 1, 2, 6, 10, 16, and 24 hours post-dose on Days 1 and 7

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2	2.33 Ratio Geometric Coefficient of Variation 22.2	1.95 Ratio Geometric Coefficient of Variation 28.6	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose on Days 1 (baseline) and 7

FPG was measured predose on Days 1 and 7. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 7. FPG is presented as mean change from baseline with a standard error.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=7 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=9 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	-23.57 mg/dL Standard Error 10.75	-39.00 mg/dL Standard Error 8.44	-59.11 mg/dL Standard Error 7.09	-11.13 mg/dL Standard Error 7.26	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose on Days 1 (baseline) and 14

FPG was measured predose on Days 1 and 14. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 14. FPG is presented as mean change from baseline with a standard error.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=7 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	-41.29 mg/dL Standard Error 11.22	-48.50 mg/dL Standard Error 13.21	-59.25 mg/dL Standard Error 4.98	-13.50 mg/dL Standard Error 9.54	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (predose and before food on Day 1) and up to 24 hours post Day 7 dose

The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Blood samples for glucose were collected immediately prior to, and after each meal. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Blood for plasma glucose concentrations was obtained at predose Day 1 at pre meal (breakfast), 0.5, 1, 2, 3, 4 (pre lunch), 4.5, 5, 6, 7, 10 (pre dinner), 10.5, 11, 12, 13, 15 and 23 hours post breakfast meal; and on Day 7 at 1 (pre breakfast), 1.5, 2, 3, 4, 5 (pre lunch), 5.5, 6, 7, 8, 11 (pre dinner), 11.5, 12, 13, 14, 16, 24 hours post dose. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with fixed effects for treatment, day and treatment by day interaction, a random effect for participant, and baseline 24-hour WMG as a covariate. WMG is presented as least squares mean with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=6 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	-24.08 mg/dL Interval -45.46 to -2.71	-27.54 mg/dL Interval -46.39 to -8.69	-53.64 mg/dL Interval -75.2 to -32.08	2.36 mg/dL Interval -16.2 to 20.92	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (predose and before food on Day 1) and up to 24 hours post Day 14 dose

The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Blood samples for glucose were collected immediately prior to and after each meal. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Blood for plasma glucose concentrations was obtained on Day -1 at pre meal (breakfast), 0.5, 1, 2, 3, 4 (pre lunch), 4.5, 5, 6, 7, 10 (pre dinner), 10.5, 11, 12, 13, 15 and 23 hours post breakfast meal; and on Day 14 at 1 (pre breakfast), 1.5, 2, 3, 4, 5 (pre lunch), 5.5, 6, 7, 8, 11(pre dinner), 11.5, 12, 13, 14, 16, 24 hours post dose. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with fixed effects for treatment, day and treatment by day interaction, a random effect for participant, and baseline 24-hour WMG as a covariate. WMG is presented as least squares mean with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=6 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=6 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1	-37.24 mg/dL Interval -58.61 to -15.86	-45.63 mg/dL Interval -64.49 to -26.78	-52.20 mg/dL Interval -73.76 to -30.64	-2.00 mg/dL Interval -20.56 to 16.56	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose on Days 1 (baseline) and 14

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-45.89 mg/dL Interval -56.44 to -35.33	-39.80 mg/dL Interval -48.27 to -31.33	-14.69 mg/dL Interval -43.93 to 14.55	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose on Days 1 (baseline) and 19

FPG was measured predose on Days 1 and 19. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 19. FPG is presented as least squares mean change from baseline with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-44.22 mg/dL Interval -54.77 to -33.66	-47.33 mg/dL Interval -55.8 to -38.86	-16.74 mg/dL Interval -45.98 to 12.51	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose on Days 1 (baseline) and 24

FPG was measured predose on Days 1 and 24. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 24. FPG is presented as least squares mean change from baseline with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=17 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-40.14 mg/dL Interval -51.0 to -29.27	-50.14 mg/dL Interval -59.3 to -40.99	-44.73 mg/dL Interval -73.97 to -15.49	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose on Days 1 (baseline) and 29

FPG was measured predose on Days 1 and 29. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 29. FPG is presented as least squares mean change from baseline with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-52.54 mg/dL Interval -63.74 to -41.33	-52.06 mg/dL Interval -61.21 to -42.91	-37.55 mg/dL Interval -66.8 to -8.31	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (predose and before food on Day 1) and up to 24 hours post Day 14 dose

The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 14 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 14 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-47.52 mg/dL Interval -56.82 to -38.22	-51.24 mg/dL Interval -58.02 to -44.45	-3.84 mg/dL Interval -30.31 to 22.63	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (predose and before food on Day 1) and up to 24 hours post Day 19 dose

The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 19 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 19 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=13 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-52.23 mg/dL Interval -61.54 to -42.93	-57.43 mg/dL Interval -64.21 to -50.64	-18.22 mg/dL Interval -44.69 to 8.25	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (predose and before food on Day 1) and up to 24 hours post Day 24 dose

The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 24 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 24 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-50.44 mg/dL Interval -59.89 to -40.99	-60.66 mg/dL Interval -67.6 to -53.72	-26.71 mg/dL Interval -53.18 to -0.24	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (predose and before food on Day 1) and up to 24 hours post Day 29 dose

The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 29 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 29 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=11 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=5 Participants T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	-53.44 mg/dL Interval -62.89 to -43.99	-59.72 mg/dL Interval -66.66 to -52.78	-29.96 mg/dL Interval -56.43 to -3.49	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 1, 2, 6, 10, 16, 24 hours post dose on Days 1, 7, 14, 19, 24 (T2DM) and Days 1 and 7 (Non-Diabetic Overweight/Obese); predose and 1, 2, 6, 10, 16, 24, 72, 96. and 120 hours post dose on Day 14 (Non-Diabetic Overweight/Obese) and Day 29 (T2DM).

Cmax was the maximum observed concentration of MK-8521 in plasma after administration. Plasma samples were collected from predose to 120 hours postdose for determination of Cmax. Per protocol, Cmax in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 1	0.35 nM Geometric Coefficient of Variation 48.0	0.411 nM Geometric Coefficient of Variation 32.1	—	—	—	—	—	—	—	—	—
Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 24	2.85 nM Geometric Coefficient of Variation 33.1	—	—	—	—	—	—	—	—	—	—
Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 7	0.719 nM Geometric Coefficient of Variation 34.6	0.742 nM Geometric Coefficient of Variation 38.7	—	—	—	—	—	—	—	—	—
Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 14	1.43 nM Geometric Coefficient of Variation 35.8	1.72 nM Geometric Coefficient of Variation 20.0	—	—	—	—	—	—	—	—	—
Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 19	2.27 nM Geometric Coefficient of Variation 38.6	—	—	—	—	—	—	—	—	—	—
Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 29	3.14 nM Geometric Coefficient of Variation 34.1	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose on Days 2 (sampled 24 hours after Day 1 dose) and 7, 14, 19, 24, and 29

Ctrough was the lowest observed concentration of MK-8521 in plasma. Plasma samples were collected predose on Day 2 (sampled after the Day 1 dose and prior to Day 2 dose), 7, 14, 19, 24, and 29 for determination of Ctrough. Per protocol, Ctrough in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Ctrough is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 19	1.61 nM Geometric Coefficient of Variation 33.8	—	—	—	—	—	—	—	—	—	—
Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 7	0.533 nM Geometric Coefficient of Variation 32.7	0.492 nM Geometric Coefficient of Variation 29.1	—	—	—	—	—	—	—	—	—
Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 14	1.07 nM Geometric Coefficient of Variation 36.0	1.12 nM Geometric Coefficient of Variation 21.8	—	—	—	—	—	—	—	—	—
Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 24	2.02 nM Geometric Coefficient of Variation 30.6	—	—	—	—	—	—	—	—	—	—
Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 29	2.47 nM Geometric Coefficient of Variation 29.9	—	—	—	—	—	—	—	—	—	—
Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 1	0.331 nM Geometric Coefficient of Variation 45.5	0.388 nM Geometric Coefficient of Variation 32.8	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 120 hours postdose for determination of Tmax. Per protocol, Tmax in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Tmax is presented as median with a full range.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=18 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=8 Participants T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 29	10 Hours Interval 1.0 to 24.0	—	—	—	—	—	—	—	—	—	—
Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 1	16 Hours Interval 10.0 to 24.0	16 Hours Interval 10.0 to 24.0	—	—	—	—	—	—	—	—	—
Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 7	10 Hours Interval 1.0 to 16.0	10 Hours Interval 10.0 to 10.0	—	—	—	—	—	—	—	—	—
Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 14	6 Hours Interval 1.0 to 10.0	6 Hours Interval 6.0 to 10.0	—	—	—	—	—	—	—	—	—
Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 19	6 Hours Interval 6.0 to 10.0	—	—	—	—	—	—	—	—	—	—
Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2 Day 24	6 Hours Interval 6.0 to 16.0	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 1, 2, 6, 10, 16, 24, 72, 96 and 120 hours post dose on Day 29

t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 120 hours postdose for determination of t1/2. Per protocol, t1/2 was measured on Day 29 which is the longest time point for sampling for T2DM participants 1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=16 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Apparent Terminal Half Life (t1/2) of MK-8521 on Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2	15.4 Hours Geometric Coefficient of Variation 10.2	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 1, 2, 6, 10, 16, and 24 hours post dose on Day 14

t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 24 hours postdose for determination of t1/2. Per protocol, t1/2 was measured on Day 14 which is the longest time point for sampling for non-diabetic overweight/obese participants 1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.

Outcome measures

Outcome measures
Measure	Part 1: MK-8521 64 μg/Day n=8 Participants Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: Placebo for MK-8521-T2DM T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule.	Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule.
Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Non-Diabetic Overweight/Obese Participants in Part 2	14.4 Hours Geometric Coefficient of Variation 10.8	—	—	—	—	—	—	—	—	—	—

Deaths: 0 deaths

Part 2: MK-8521 120 μg/Day-Non-Diabetic Overweight/Obese

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Part 1: MK-8521 64 μg/Day n=9 participants at risk Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=7 participants at risk T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=8 participants at risk T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 participants at risk T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day n=11 participants at risk T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day n=11 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day n=8 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 n=8 participants at risk T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: MK-8521 64 μg/Day T2DM n=18 participants at risk Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 µg on Days 1 to 7 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 120 μg/Day T2DM n=18 participants at risk T2DM participants received once daily subcutaneous MK-8521 120 µg on Days 8 to 14 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 180 μg/Day T2DM n=18 participants at risk T2DM participants received once daily subcutaneous MK-8521 180 µg on Days 15 to 19 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 240 μg/Day T2DM n=18 participants at risk T2DM participants received once daily subcutaneous MK-8521 240 µg on Days 20 to 24 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 300 μg/Day T2DM n=15 participants at risk T2DM participants received once daily subcutaneous MK-8521 300 µg on Days 25 to 29 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: Liraglutide 0.6 mg/Day T2DM n=14 participants at risk T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Days 1 to 7 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.	Part 2: Liraglutide 1.2 mg/Day T2DM n=13 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.	Part 2: Liraglutide 1.8 mg/Day T2DM n=13 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 15 to 29 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.	Part 2: Placebo for MK-8521-T2DM n=6 participants at risk T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 μg/Day-Non-Diabetic Overweight/Obese n=8 participants at risk Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg on Days 1 to 7 as part of the MK-8521 64/120 µg treatment sequence.	Part 2: MK-8521 120 μg/Day-Non-Diabetic Overweight/Obese n=8 participants at risk Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg on Days 8 to 14 as part of the MK-8521 64/120 µg treatment sequence.
Cardiac disorders Sick sinus syndrome	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Cardiac disorders Supraventricular tachycardia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Convulsion	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Presyncope	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.

Other adverse events

Other adverse events
Measure	Part 1: MK-8521 64 μg/Day n=9 participants at risk Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 120 μg/Day n=7 participants at risk T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.	Part 1: MK-8521 34 μg/Day n=8 participants at risk T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: MK-8521 72 μg/Day n=8 participants at risk T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.	Part 1: Liraglutide 0.6 mg/Day n=11 participants at risk T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.2 mg/Day n=11 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Liraglutide 1.8 mg/Day n=8 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.	Part 1: Placebo for MK-8521 n=8 participants at risk T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.	Part 2: MK-8521 64 μg/Day T2DM n=18 participants at risk Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 µg on Days 1 to 7 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 120 μg/Day T2DM n=18 participants at risk T2DM participants received once daily subcutaneous MK-8521 120 µg on Days 8 to 14 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 180 μg/Day T2DM n=18 participants at risk T2DM participants received once daily subcutaneous MK-8521 180 µg on Days 15 to 19 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 240 μg/Day T2DM n=18 participants at risk T2DM participants received once daily subcutaneous MK-8521 240 µg on Days 20 to 24 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: MK-8521 300 μg/Day T2DM n=15 participants at risk T2DM participants received once daily subcutaneous MK-8521 300 µg on Days 25 to 29 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.	Part 2: Liraglutide 0.6 mg/Day T2DM n=14 participants at risk T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Days 1 to 7 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.	Part 2: Liraglutide 1.2 mg/Day T2DM n=13 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.	Part 2: Liraglutide 1.8 mg/Day T2DM n=13 participants at risk T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 15 to 29 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.	Part 2: Placebo for MK-8521-T2DM n=6 participants at risk T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.	Part 2: MK-8521 64 μg/Day-Non-Diabetic Overweight/Obese n=8 participants at risk Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg on Days 1 to 7 as part of the MK-8521 64/120 µg treatment sequence.	Part 2: MK-8521 120 μg/Day-Non-Diabetic Overweight/Obese n=8 participants at risk Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg on Days 8 to 14 as part of the MK-8521 64/120 µg treatment sequence.
Cardiac disorders Tachycardia paroxysmal	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Cardiac disorders Palpitations	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Cardiac disorders Sinus tachycardia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Cardiac disorders Supraventricular tachycardia	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Cardiac disorders Tachycardia	22.2% 2/9 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 1/7 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Cardiac disorders Ventricular extrasystoles	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Cardiac disorders Ventricular tachycardia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Ear and labyrinth disorders Ear pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	15.4% 2/13 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Eye disorders Vision blurred	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Abdominal distension	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Abdominal pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	11.1% 2/18 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	11.1% 2/18 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	15.4% 2/13 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	23.1% 3/13 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Aphthous stomatitis	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Change of bowel habit	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Constipation	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	22.2% 4/18 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	15.4% 2/13 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Diarrhoea	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	27.3% 3/11 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	22.2% 4/18 • Number of events 6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	33.3% 6/18 • Number of events 6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	20.0% 3/15 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	35.7% 5/14 • Number of events 6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	30.8% 4/13 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Dry mouth	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Dyspepsia	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	27.3% 3/11 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	11.1% 2/18 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Flatulence	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Gingival pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 1/7 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Haematochezia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Haemorrhoids	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Mouth ulceration	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Nausea	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 1/7 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	36.4% 4/11 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	11.1% 2/18 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	22.2% 4/18 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	27.8% 5/18 • Number of events 6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	35.7% 5/14 • Number of events 7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	15.4% 2/13 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	38.5% 5/13 • Number of events 6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Regurgitation	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Retching	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Toothache	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Gastrointestinal disorders Vomiting	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	15.4% 2/13 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Application site dermatitis	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Application site erythema	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Application site irritation	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Application site pruritus	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Asthenia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Catheter site erythema	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Catheter site haemorrhage	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Oedema peripheral	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Catheter site oedema	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Chest pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Early satiety	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Feeling cold	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Feeling hot	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Influenza like illness	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Injection site erythema	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Injection site haemorrhage	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 1/7 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Injection site injury	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Injection site macule	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Peripheral swelling	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Pyrexia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Vessel puncture site erythema	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Vessel puncture site haemorrhage	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Vessel puncture site pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
General disorders Xerosis	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Infections and infestations Hordeolum	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Infections and infestations Localised infection	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Infections and infestations Tooth infection	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Infections and infestations Urinary tract infection	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Infections and infestations Viral infection	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Infections and infestations Viral pharyngitis	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Injury, poisoning and procedural complications Post-traumatic pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 1/7 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	15.4% 2/13 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Investigations Lipase increased	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	22.2% 4/18 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Investigations Weight decreased	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	11.1% 2/18 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 2/14 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Metabolism and nutrition disorders Increased appetite	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	11.1% 2/18 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Dizziness	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Dysgeusia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Headache	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 1/7 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	27.3% 3/11 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 3/18 • Number of events 3 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	22.2% 4/18 • Number of events 5 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	23.1% 3/13 • Number of events 4 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Hypoaesthesia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Paraesthesia	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Sinus headache	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Somnolence	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Nervous system disorders Tremor	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Psychiatric disorders Anxiety	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Psychiatric disorders Dysthymic disorder	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Psychiatric disorders Insomnia	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Renal and urinary disorders Dysuria	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	9.1% 1/11 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Respiratory, thoracic and mediastinal disorders Paranasal sinus discomfort	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Ecchymosis	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.1% 1/14 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Nail ridging	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Pruritus	11.1% 1/9 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	18.2% 2/11 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	25.0% 2/8 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	11.1% 2/18 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Rash	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	6.7% 1/15 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 2 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	12.5% 1/8 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	14.3% 1/7 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	16.7% 1/6 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Skin and subcutaneous tissue disorders Skin wrinkling	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Vascular disorders Flushing	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	5.6% 1/18 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.
Vascular disorders Hypotension	0.00% 0/9 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/7 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/11 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/18 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/15 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/14 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	7.7% 1/13 • Number of events 1 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/13 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/6 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.	0.00% 0/8 • Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2 All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.
Publication restrictions are in place

Restriction type: OTHER